Evidence map›Paper›PMID 42311904›Full record

ReviewClinical kidney journal2026

Phosphate-latest news and ongoing trials.

Arti Sharma Parpia, Ruchi Kumra, Caleb Mansell, Ziv Harel, Jeffrey Perl, Orit Kliuk Ben-Bassat, Ron Wald

Abstract readReview
In one paragraph

Review in Clinical kidney journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Arti Sharma ParpiaDivision of Nephrology, St. Michael's Hospital, Toronto, ON, Canada.
Ruchi KumraCollege of Pharmacy, University of Manitoba, Winnipeg, MB, Canada.
Caleb MansellFaculty of Arts and Sciences, Washington University St. Louis, St. Louis, MO, USA.
Ziv HarelDivision of Nephrology, St. Michael's Hospital, Toronto, ON, Canada.
Jeffrey PerlDivision of Nephrology, St. Michael's Hospital, Toronto, ON, Canada.
Orit Kliuk Ben-BassatDepartment of Nephrology and Hypertension, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.ORCID 0000-0002-7932-1717
Ron WaldDivision of Nephrology, St. Michael's Hospital, Toronto, ON, Canada.ORCID 0000-0003-4411-8169

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hyperphosphatemia is present in nearly all patients with kidney failure who receive maintenance dialysis. The direct toxicity of elevated phosphate concentrations had been inferred from basic experimentation and large epidemiologic studies. This has influenced clinical practice in which great efforts are expended in normalizing serum phosphate concentration. Targeted dietary strategies, optimization of dialysis and phosphate-lowering medications are all effective at lowering serum phosphate levels yet each pose challenges for patients and clinicians. The effect of these interventions, individually and collectively, on patient-centered clinical outcomes is also unclear. We will review the evidence from clinical trials for each of these measures and discuss ongoing research that is testing optimal targets for serum phosphate.

Indexed as

chronic hemodialysisclinical trialperitoneal dialysisphosphate binderphosphatemia

Identifiers

PMID42311904
PMCPMC13270310

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.